

Jesse J Swen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4294428/publications.pdf>

Version: 2024-02-01

110
papers

4,343
citations

172207

29
h-index

123241

61
g-index

113
all docs

113
docs citations

113
times ranked

4443
citing authors

#	ARTICLE	IF	CITATIONS
1	Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone). <i>European Journal of Human Genetics</i> , 2022, 30, 1105-1113.	1.4	22
2	Towards Fixed Dosing of Tocilizumab in ICU-Admitted COVID-19 Patients: Results of an Observational Population Pharmacokinetic and Descriptive Pharmacodynamic Study. <i>Clinical Pharmacokinetics</i> , 2022, 61, 231-247.	1.6	9
3	Abnormal Results of Newborn Screening for SCID After Azathioprine Exposure In Utero: Benefit of TPMT Genotyping in Both Mother and Child. <i>Journal of Clinical Immunology</i> , 2022, 42, 199-202.	2.0	6
4	Application of long-read sequencing to elucidate complex pharmacogenomic regions: a proof of principle. <i>Pharmacogenomics Journal</i> , 2022, 22, 75-81.	0.9	17
5	Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs. <i>European Journal of Human Genetics</i> , 2022, 30, 1114-1120.	1.4	37
6	UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients. <i>European Journal of Cancer</i> , 2022, 162, 148-157.	1.3	27
7	Pharmacogenomic testing in paediatrics: Clinical implementation strategies. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 4297-4310.	1.1	12
8	Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 62-68.	2.3	32
9	A Systematic Review on Disease-Drug-Drug Interactions with immunomodulating drugs: A Critical Appraisal of Risk Assessment and Drug Labelling. <i>British Journal of Clinical Pharmacology</i> , 2022, , .	1.1	3
10	Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib. <i>Cancers</i> , 2022, 14, 2838.	1.7	1
11	Volumetric microsampling for simultaneous remote immunosuppressant and kidney function monitoring in outpatient kidney transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 4854-4869.	1.1	20
12	Pharmacogenomics decision support in the U-PGx project: Results and advice from clinical implementation across seven European countries. <i>PLoS ONE</i> , 2022, 17, e0268534.	1.1	20
13	Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing. <i>Clinical Pharmacokinetics</i> , 2021, 60, 89-102.	1.6	6
14	Pharmacogenomic Determinants of Interindividual Drug Response Variability: From Discovery to Implementation. <i>Genes</i> , 2021, 12, 393.	1.0	1
15	Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 150-200.	1.0	89
16	Model-Based Estimation of Iohexol Plasma Clearance for Pragmatic Renal Function Determination in the Renal Transplantation Setting. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1201-1215.	1.6	5
17	Population pharmacokinetics and genetics of oral meltdose tacrolimus (Envarsus) in stable adult liver transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4262-4272.	1.1	8
18	Safety and pharmacokinetic analysis of UGT1A1 genotype-guided dosing of irinotecan.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3574-3574.	0.8	3

#	ARTICLE	IF	CITATIONS
19	Model-informed precision dosing to optimise immunosuppressive therapy in renal transplantation. <i>Drug Discovery Today</i> , 2021, 26, 2527-2546.	3.2	12
20	Toward predicting CYP2D6-mediated variable drug response from CYP2D6 gene sequencing data. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	42
21	Applying Next-Generation Sequencing Platforms for Pharmacogenomic Testing in Clinical Practice. <i>Frontiers in Pharmacology</i> , 2021, 12, 693453.	1.6	26
22	Substrate specificity of CYP2D6 genetic variants. <i>Pharmacogenomics</i> , 2021, 22, 1081-1089.	0.6	9
23	The end of the laboratory developed test as we know it? Recommendations from a national multidisciplinary taskforce of laboratory specialists on the interpretation of the IVDR and its complications. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 491-497.	1.4	27
24	Predictive genetic biomarkers for the efficacy of methotrexate in rheumatoid arthritis: a systematic review. <i>Pharmacogenomics Journal</i> , 2020, 20, 159-168.	0.9	10
25	Repurposing of Diagnostic Whole Exome Sequencing Data of 1,583 Individuals for Clinical Pharmacogenetics. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 617-627.	2.3	24
26	One non-believer: Response to 'Obviously Nine Believers: Actionable Germline Genetic Variants for Pre-emptive Pharmacogenetic Testing'. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 126, 7-8.	1.2	1
27	Evaluation of Current Regulation and Guidelines of Pharmacogenomic Drug Labels: Opportunities for Improvements. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1240-1255.	2.3	62
28	Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. <i>Clinical and Translational Science</i> , 2020, 13, 116-124.	1.5	353
29	Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines. <i>European Journal of Human Genetics</i> , 2020, 28, 508-517.	1.4	127
30	Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines. <i>Frontiers in Pharmacology</i> , 2020, 11, 567048.	1.6	28
31	Precision Medicine Using Pharmacogenomic Panel-Testing. <i>Advances in Molecular Pathology</i> , 2020, 3, 131-142.	0.2	1
32	Comparison of the Impact of Pharmacogenetic Variability on the PK of Slow Release and Immediate Release Tacrolimus Formulations. <i>Genes</i> , 2020, 11, 1205.	1.0	5
33	Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study. <i>Pharmacogenetics and Genomics</i> , 2020, 30, 131-144.	0.7	26
34	The Clinical Impact of the C ₀ /D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients. <i>Frontiers in Pharmacology</i> , 2020, 11, 1142.	1.6	27
35	Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 2890.	1.0	84
36	Distinct Effects of Inflammation on Cytochrome P450 Regulation and Drug Metabolism: Lessons from Experimental Models and a Potential Role for Pharmacogenetics. <i>Genes</i> , 2020, 11, 1509.	1.0	55

#	ARTICLE	IF	CITATIONS
37	Using Personal Genomic Data within Primary Care: A Bioinformatics Approach to Pharmacogenomics. <i>Genes</i> , 2020, 11, 1443.	1.0	8
38	Technologies for Pharmacogenomics: A Review. <i>Genes</i> , 2020, 11, 1456.	1.0	37
39	Exposure–response analysis of endoxifen serum concentrations in early-breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 1141-1152.	1.1	10
40	Assessing the Implementation of Pharmacogenomic Panel-Testing in Primary Care in the Netherlands Utilizing a Theoretical Framework. <i>Journal of Clinical Medicine</i> , 2020, 9, 814.	1.0	20
41	Educating the Next Generation of Pharmacogenomics Experts: Global Educational Needs and Concepts. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 313-316.	2.3	14
42	A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 720-737.	1.3	90
43	Validation of a clinical pharmacogenetic model to predict methotrexate nonresponse in rheumatoid arthritis patients. <i>Pharmacogenomics</i> , 2019, 20, 85-93.	0.6	13
44	Pharmacogenomics Education and Clinical Practice Guidelines. , 2019, , 395-414.		2
45	Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors. <i>Pharmacogenomics Journal</i> , 2019, 19, 473-479.	0.9	9
46	A pilot study of the implementation of pharmacogenomic pharmacist initiated pre-emptive testing in primary care. <i>European Journal of Human Genetics</i> , 2019, 27, 1532-1541.	1.4	38
47	Pharmacist-Initiated Pre-Emptive Pharmacogenetic Panel Testing with Clinical Decision Support in Primary Care: Record of PGx Results and Real-World Impact. <i>Genes</i> , 2019, 10, 416.	1.0	58
48	Estimated nationwide impact of implementing a preemptive pharmacogenetic panel approach to guide drug prescribing in primary care in The Netherlands. <i>BMC Medicine</i> , 2019, 17, 110.	2.3	56
49	Development of the <sc>PG</sc>â€Passport: A Panel of Actionable Germline Genetic Variants for Preâ€Emptive Pharmacogenetic Testing. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 866-873.	2.3	73
50	A cost analysis of upfront DPYD genotypeâ€guided dose individualisation in fluoropyrimidine-based anticancer therapy. <i>European Journal of Cancer</i> , 2019, 107, 60-67.	1.3	65
51	Confirmation practice in pharmacogenetic testing; how good is good enough?. <i>Clinica Chimica Acta</i> , 2019, 490, 77-80.	0.5	2
52	Pharmacogenetic Information in Clinical Guidelines: The European Perspective. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 795-801.	2.3	71
53	A nationwide cross-sectional survey of pharmacy students on pharmacogenetic testing in The Netherlands. <i>Pharmacogenomics</i> , 2018, 19, 311-319.	0.6	16
54	A Genetic Polymorphism in <i>CTLA-4</i> Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 2350-2356.	3.2	7

#	ARTICLE	IF	CITATIONS
55	Implementing pharmacogenomics decision support across seven European countries: The Ubiquitous Pharmacogenomics (U-PGx) project. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2018, 25, 893-898.	2.2	67
56	<i>SLC04A1</i> , <i>SLC22A2</i> and <i>SLC28A2</i> variants not related to methotrexate efficacy or toxicity in rheumatoid arthritis patients. <i>Pharmacogenomics</i> , 2018, 19, 613-619.	0.6	2
57	Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 599-618.	2.3	186
58	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 210-216.	2.3	407
59	Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD Variants. <i>Genes</i> , 2018, 9, 585.	1.0	10
60	Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers. <i>European Journal of Cancer</i> , 2018, 104, 210-218.	1.3	14
61	DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. <i>Lancet Oncology</i> , 2018, 19, 1459-1467.	5.1	238
62	Effects of age and genetic variations in <i>VKORC1</i> , <i>CYP2C9</i> and <i>CYP3A4</i> on the phenprocoumon dose in pediatric patients. <i>Pharmacogenomics</i> , 2018, 19, 1195-1202.	0.6	2
63	Therapeutic drug monitoring of tacrolimus and mycophenolic acid in outpatient renal transplant recipients using a volumetric dried blood spot sampling device. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2889-2902.	1.1	70
64	Implementation of Pharmacogenomics in Everyday Clinical Settings. <i>Advances in Pharmacology</i> , 2018, 83, 219-246.	1.2	33
65	A prospective study on the effect of endoxifen concentration and CYP2D6 phenotypes on clinical outcome in early stage breast cancer patients receiving adjuvant tamoxifen. <i>Journal of Clinical Oncology</i> , 2018, 36, 523-523.	0.8	3
66	A nationwide survey of pharmacists' perception of pharmacogenetics in the context of a clinical decision support system containing pharmacogenetics dosing recommendations. <i>Pharmacogenomics</i> , 2017, 18, 215-225.	0.6	40
67	Influence of CYP2C8 polymorphisms on imatinib steady-state trough level in chronic myeloid leukemia and gastrointestinal stromal tumor patients. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 223-226.	0.7	5
68	Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 227-231.	0.7	5
69	What do we need to make genetic biomarker-guided treatment for renal cell carcinoma a reality?. <i>Pharmacogenomics</i> , 2017, 18, 1-4.	0.6	1
70	Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis. <i>Acta Oncologica</i> , 2017, 56, 582-589.	0.8	27
71	Flexible and Scalable Full-Length CYP2D6 Long Amplicon PacBio Sequencing. <i>Human Mutation</i> , 2017, 38, 310-316.	1.1	69
72	Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib. <i>European Journal of Cancer</i> , 2017, 86, 226-232.	1.3	13

#	ARTICLE	IF	CITATIONS
73	The effect of rs5758550 on <i>CYP2D6</i> phenotype and formation of endoxifen in breast cancer patients using tamoxifen. <i>Pharmacogenomics</i> , 2017, 18, 1125-1132.	0.6	19
74	Pathway analysis to identify genetic variants associated with efficacy of adalimumab in rheumatoid arthritis. <i>Pharmacogenomics</i> , 2017, 18, 945-953.	0.6	6
75	The Ubiquitous Pharmacogenomics consortium: making effective treatment optimization accessible to every European citizen. <i>Pharmacogenomics</i> , 2017, 18, 1041-1045.	0.6	19
76	Meta-analysis on the association of <i>VEGFR1</i> genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients. <i>Oncotarget</i> , 2017, 8, 1204-1212.	0.8	6
77	Evaluation of clinical implementation of prospective <i>DPYD</i> genotyping in 5-fluorouracil- or capecitabine-treated patients. <i>Pharmacogenomics</i> , 2016, 17, 721-729.	0.6	24
78	A brighter future for the implementation of pharmacogenomic testing. <i>European Journal of Human Genetics</i> , 2016, 24, 1658-1660.	1.4	23
79	Insulin-like growth factor 1 receptor expression and <i>IGF1R</i> 3129G>T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOC 2010-01). <i>Breast Cancer Research</i> , 2016, 18, 3.	2.2	30
80	A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 605-618.	1.5	19
81	Prospective <i>DPYD</i> genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time. <i>European Journal of Cancer</i> , 2016, 54, 40-48.	1.3	110
82	Clinical validation study of genetic markers for capecitabine efficacy in metastatic colorectal cancer patients. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 279-288.	0.7	4
83	Farmacogenetica in uw spreekkamer. <i>Bijblijven (Amsterdam, Netherlands)</i> , 2015, 31, 578-588.	0.0	0
84	<i>FcGR</i> genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis. <i>Pharmacogenomics</i> , 2015, 16, 373-381.	0.6	26
85	<i>CYP3A5</i> and <i>ABCB1</i> Polymorphisms as Predictors for Sunitinib Outcome in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2015, 68, 621-629.	0.9	75
86	Translating <i>DPYD</i> genotype into DPD phenotype: using the <i>DPYD</i> gene activity score. <i>Pharmacogenomics</i> , 2015, 16, 1275-1284.	0.6	81
87	GenoChip <i>CYP2D6</i> microarray as a method to genotype for <i>CYP2D6</i> variants: results of a validation study in a Caucasian population. <i>Pharmacogenomics</i> , 2015, 16, 681-687.	0.6	9
88	Association of single nucleotide polymorphisms in <i>IL8</i> and <i>IL13</i> with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1477-1484.	0.8	19
89	Evidence synthesis and guideline development in genomic medicine: current status and future prospects. <i>Genetics in Medicine</i> , 2015, 17, 63-67.	1.1	16
90	<i>CYP3A5</i> and <i>ABCB1</i> polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4548-4548.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process. <i>Current Drug Metabolism</i> , 2014, 15, 209-217.	0.7	341
92	Challenges in CYP2D6 Phenotype Assignment from Genotype Data: A Critical Assessment and Call for Standardization. <i>Current Drug Metabolism</i> , 2014, 15, 218-232.	0.7	147
93	Pharmacogenetics of taste: turning bitter pills sweet?. <i>Pharmacogenomics</i> , 2014, 15, 111-119.	0.6	6
94	Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase (DPD) splice site variant: the need for further revision of dose and schedule. <i>Internal and Emergency Medicine</i> , 2014, 9, 481-482.	1.0	2
95	Pharmacogenetics in Transplant Patients: Mind the Mix. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 443-444.	2.3	2
96	Genetic risk factors for drug-induced liver injury in rheumatoid arthritis patients using low-dose methotrexate. <i>Pharmacogenomics</i> , 2013, 14, 63-73.	0.6	18
97	Exploratory analysis of 1936 SNPs in ADME genes for association with busulfan clearance in adult hematopoietic stem cell recipients. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 675-683.	0.7	17
98	Effect of genetic variants <i>GSTA1</i> and <i>CYP39A1</i> and age on busulfan clearance in pediatric patients undergoing hematopoietic stem cell transplantation. <i>Pharmacogenomics</i> , 2013, 14, 1683-1690.	0.6	32
99	Centres of Excellence Course in Pharmacogenetics, 25-28 June 2012. <i>European Journal of Hospital Pharmacy</i> , 2013, 20, 132-132.	0.5	0
100	Association analysis of polymorphisms in genes related to sunitinib pharmacokinetics.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4580-4580.	0.8	0
101	The challenges of developing a "medical-grade"™ genome. <i>Pharmacogenomics</i> , 2012, 13, 369-372.	0.6	2
102	Just how feasible is pharmacogenetic testing in the primary healthcare setting?. <i>Pharmacogenomics</i> , 2012, 13, 507-509.	0.6	22
103	Alternative methods to a TaqMan assay to detect a tri-allelic single nucleotide polymorphism rs757210 in the HNF1 β gene. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 279-84.	1.4	7
104	Genetic risk factors for type 2 diabetes mellitus and response to sulfonylurea treatment. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 461-468.	0.7	7
105	SNPs and Haplotypes in <i>DPYD</i> and Outcome of Capecitabine Letter. <i>Clinical Cancer Research</i> , 2011, 17, 5833-5834.	3.2	5
106	Comment: Global Formulary Review: How Do We Integrate Pharmacogenomic Information?. <i>Annals of Pharmacotherapy</i> , 2011, 45, 1030-1030.	0.9	0
107	Effect of <i>CYP2C9</i> polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus. <i>Pharmacogenomics</i> , 2010, 11, 1517-1523.	0.6	22
108	Translating Pharmacogenomics: Challenges on the Road to the Clinic. <i>PLoS Medicine</i> , 2007, 4, e209.	3.9	174

#	ARTICLE	IF	CITATIONS
109	Why We Need to Take a Closer Look at Genetic Contributions to CYP3A Activity. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	12
110	Cost-Effectiveness of Pharmacogenomics-Guided Prescribing to Prevent Gene-Drug-Related Deaths: A Decision-Analytic Model. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	9